Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Clinical Validation of a Novel Quantitative Assay for the Detection of MGMT Methylation in Glioblastoma Patients

Rocio Rosas-Alonso
* ,
Julian Colmenarejo-Fernandez
,
Olga Pernia
,
Carlos Rodriguez-Antolin
,
Isabel Esteban
,
Ismael Ghanem
,
Dario Sanchez-cabrero
,
Itsaso Losantos-Garcia
,
Javier de Castro
,
Virginia Martinez-Marin
,
Inmaculada Ibanez de Caceres
* ORCID logo
Version 1 : Received: 3 August 2020 / Approved: 4 August 2020 / Online: 4 August 2020 (11:34:58 CEST)

How to cite: Rosas-Alonso, R.; Colmenarejo-Fernandez, J.; Pernia, O.; Rodriguez-Antolin, C.; Esteban, I.; Ghanem, I.; Sanchez-cabrero, D.; Losantos-Garcia, I.; de Castro, J.; Martinez-Marin, V.; Ibanez de Caceres, I. Clinical Validation of a Novel Quantitative Assay for the Detection of MGMT Methylation in Glioblastoma Patients. Preprints 2020, 2020080096. https://doi.org/10.20944/preprints202008.0096.v1 Rosas-Alonso, R.; Colmenarejo-Fernandez, J.; Pernia, O.; Rodriguez-Antolin, C.; Esteban, I.; Ghanem, I.; Sanchez-cabrero, D.; Losantos-Garcia, I.; de Castro, J.; Martinez-Marin, V.; Ibanez de Caceres, I. Clinical Validation of a Novel Quantitative Assay for the Detection of MGMT Methylation in Glioblastoma Patients. Preprints 2020, 2020080096. https://doi.org/10.20944/preprints202008.0096.v1

Abstract

The promoter hypermethylation of the methylguanine-DNA methyltransferase (MGMT) gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients treated with temozolamide. In this study we carried out a clinical validation of a quantitative assay for MGMT methylation detection by comparing a novel MSP custom assay using double-probe characteristics (dp_qMSP) with the conventional MSP in 100 FFPE glioblastoma samples collected from a prospective study in La Paz University Hospital. We realized both determinations and established the best cutoff for the identification of positive-methylated samples using the quantitative data obtained from dp_qMSP. Kaplan-Meier curves and ROC time dependent or ROC(t) curves were employed for the comparison of both methodologies. Our results indicate that the optimal cutoff to categorize the MGMTm positive samples by using dp_qMSP is 3.75% methylation value. We obtained similar results using both assays in the same cohort of patients, in terms of progression free survival (PFS) and overall survival (OS) when analyzing the Kaplan-Meier curves. The results of ROC(t) curves showed that dp_qMSP increases the AUC (t) in comparison with MSP for predicting PFS and OS over time. We conclude that dp_qMSP is an alternative methodology compatible with the results obtained with the conventional MSP. This easy-to-use, objective and reliable methodology provides quantitative results and improves the diagnostic precision of patients with glioblastoma in terms of PFS and OS, making it a more competitive assay, suitable for clinical practice.

Keywords

MGMT methylation; MSP; dp_qMSP; glioblastoma

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.